ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Diarylpropionitrile, a selective agonist of estrogen receptor β, protects the kidney against ischemia-reperfusion injury and enhances the repair of tubular epithelial cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ischemia-reperfusion injury (I/R), a leading cause of acute kidney injury (AKI) and often progressing to chronic kidney disease (CKD), is characterized by fibrotic changes in kidney parenchyma. Estrogen exerts reno-protective effects through estrogen receptors, but the specific role of estrogen receptor β (ERβ) remains unclear. Therefore, this study aims to investigate the effects of diarylpropionitrile (DPN), a selective ERβ agonist, on kidney I/R injury and subsequent fibrosis in mice. DPN administration prevented increases in plasma creatinine and blood urea nitrogen, tubular damage, and oxidative stress following bilateral kidney I/R. DPN enhanced extracellular signal-regulated kinase 1/2 (ERK) activation and promoted tubular cell proliferation after kidney I/R. Additionally, DPN administration inhibited I/R-induced increases in interstitial expansion, collagen deposition, and expression of vimentin and α-smooth muscle actin. In contrast, DPN enhanced the proliferation of tubular epithelial cells after kidney I/R. Collectively, these findings indicate that DPN protects the kidney from I/R injury and inhibits fibrotic development, suggesting that ERβ may be considered as a potential therapeutic target for treating AKI and CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.